| (Values in U.S. Thousands) | Dec, 2025 | Jun, 2025 | Dec, 2024 | Jun, 2024 | Dec, 2023 |
| Sales | 327,450 | 115,450 | 52,330 | 15,390 | 0 |
| Sales Growth | +183.63% | +120.62% | +240.03% | unch | unch |
| Net Income | 108,830 | 11,160 | -3,760 | -5,860 | 0 |
| Net Income Growth | +875.18% | +396.81% | +35.84% | unch | unch |
Sinovac Biotech Ltd (SVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Sonovac Biotech Ltd. specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as hepatitis A and hepatitis B, influenza, `SARS`, and avian flu. Sinovac is one of the leading emerging biotechnology companies in China.
Fiscal Year End Date: 12/31